coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Stalybridge, Dukinfield & Mossley PCN, Tameside (LAD) · Health Inequalities Profile

    PCN U01630 · NHS Greater Manchester Integrated Care Board · 9 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    43,616

    Registered population

    61.6% aged 18–64

    18.0%

    Aged 65+

    ICB 14.9% · England 17.9%

    32.1%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~17,953

    Core20 residents (est.)

    Resident basis; registered basis ~14,585 · see page 3

    7,827

    Hypertension register

    +3.60% in 3 yrs · England +5.60%

    392

    SMI register

    16.7% of Tameside (LAD)'s

    1,252

    COPD register

    Reviews +5.94% in 3 yrs

    Forecast to 2030

    8,745

    Hypertension patients, 2030

    +918 on today

    70.5%

    QRISK ≥20% on statins, 2030

    +0.99pp over 3 yrs

    5.2%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    15
    Three-year change trails England across 15 measures.

    Of 25 compared measures, 15 trail England over three years, including heart failure reviews (-4.0% versus +8.7%) and hypertension control (-1.0% versus +3.6%).

    28.4 pp
    Wide practice spreads in access and deprivation.

    Phone contact ease spans 28.4 pp (Pike Medical Practice 63.2% to St. Andrew's House Surgery 91.6%), while Core20 patient share spans 53.9 pp.

    73.6%
    Current cardiovascular control exceeds England averages.

    Hypertension treated to target reaches 73.6% (England 70.3%), alongside higher heart failure review coverage (82.9% versus 78.5%) and QRISK lipid therapy (68.4% versus 63.6%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ represent 18.0% of the list alongside 509 local care-home beds

    Across 43,616 registered patients, 18.0% (7,848 patients) are aged 65+, above Tameside (LAD) (16.4%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Working-age adults (18–64) comprise 61.6% (26,855 patients; LAD 62.3%, ICB 63.3%, England 62.7%), and children aged 0–17 represent 20.4% (8,913 patients; LAD 21.3%, ICB 21.8%, England 19.6%). Recorded Gypsy or Irish Traveller and Roma groups are both 0.0%. List size is projected to grow 1.9% by 2030 (LAD 1.4%, ICB 1.6%, England 2.3%; unverified methodology). Observation periods for list and age distributions were not supplied.

    Age profile

    0–1720.4%
    18–6461.6%
    65+18.0%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Tameside (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Tameside LA)2,0472,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)83.3%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)59.2%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Tameside LA)1,0451,0219552024/25
    Falls deaths, all ages, per 100,000 (Tameside LA)32.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 share reaches 32.1% overall but ranges by 53.9 pp across practices

    The PCN Core20 share is 32.1%, above England (21.0%) but below Tameside (LAD) (40.9%) and NHS Greater Manchester Integrated Care Board (40.7%), with an average IMD decile of 4.3 (England 5.5 decile). Before targeting, weighted practice share (33.4%) differs from the PCN figure by 1.36 pp. Across practices, concentration spans 53.9 pp, from 6.6% at Pike Medical Practice to 60.5% at King Street Medical Centre, while Staveleigh Medical Centre holds the largest volume at 3,535 estimated Core20 patients. Outreach should balance high-concentration practices with high-volume lists.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    King Street60.5% · 1,938 patients
    Town Hall46.7% · 1,274 patients
    St. Andrew's44.2% · 2,613 patients
    Staveleigh42.7% · 3,535 patients
    Grosvenor35.4% · 2,202 patients
    Lockside26.9% · 2,239 patients
    Mossley Medical15.2% · 332 patients
    Millbrook Medical6.8% · 234 patients
    Pike Medical6.6% · 218 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    392

    SMI register

    0.90% recorded prevalence

    289

    Learning disability register

    0.66% recorded prevalence

    13

    Care homes, 509 beds

    In the PCN catchment

    9.7%

    Provide unpaid care

    Tameside (LAD), Census 2021

    Registers record 289 patients with learning disabilities (0.7%; LAD 0.7%, ICB 0.6%, England 0.6%) and 392 with severe mental illness (0.9%; LAD 1.0%, England 1.0%). Catchment care homes hold 509 beds across 13 sites. At borough level, Census data models an unpaid-carer ceiling of 4,231, while autumn 2025 rough sleeping was 16.

    Severe mental illness: physical health checks

    Recorded SMI checks exceed England: blood pressure checks reach 88.9% (England 83.4%) and BMI reaches 85.9% (England 82.1%). However, smoking cessation offers for patients with certain conditions fell 2.7 pp over 2023 to 2025 (England +0.1 pp).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,827

    Hypertension register

    +3.60%

    Register growth, 3 yrs

    Tameside (LAD) +5.50% · England +5.60%

    +0.86pp

    BP control, under 80

    ≤140/90 · +2.70pp aged 80+

    +918

    More patients by 2030

    Forecast 8,745 (19.30%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 18.0% (7,827 patients), above Tameside (17.4%), the ICB (14.4%) and England (15.2%). Current control exceeds benchmarks: 73.6% of hypertensive patients are treated to target (England 70.3%) and 71.1% under age 80 achieve blood pressure at or below 140/90 mmHg (England 67.8%). However, three-year control trends trail national progress: treatment to target fell 1.0% (England +3.6%) and under-80 control rose +1.2% (England +3.2%), which could reflect recall pressure (unverified locally; a recall audit would test this). Register growth (+3.6%) also trailed England (+5.6%). Higher current control alongside trailing three-year progress suggests prioritising blood pressure recall reviews to sustain clinical control.

    Lipids and statins

    Patients with QRISK ≥ 20% on lipid-lowering therapy reach 68.4% (Tameside 69.2%, ICB 67.0%, England 63.6%). However, three-year treatment growth of +1.5% trails England (+6.2%). Favourable current coverage alongside slower uptake growth indicates the PCN could prioritise structured cardiovascular risk reviews to identify eligible patients.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202687,438£2.10£1.94£1.86£183,620
    Cardiovascular (all), 2025123,460£2.99£3.15£3.33£369,145

    In 2026, the PCN prescribed 87,438 items for lipid-regulating drugs at £2.10 per item (Tameside £2.01, ICB £1.94, England £1.86), spending £20,985 more than at England's unit cost. Higher unit costs highlight an opportunity to review formulary choices without compromising clinical treatment thresholds.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +4.21%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +2.52%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 8.0% (3,260 patients; England 6.6%), with 5–19 asthma prescribing at 2,086 rate per 1,000 (England 1,488 rate). Annual asthma reviews cover 64.5% (England 65.7%), leaving an estimated 1,157 patients unreviewed. Conversely, COPD prevalence is 2.9% (1,252 patients; England 1.9%) with reviews reaching 79.3% (England 76.4%). Higher youth prescribing alongside lower review coverage may reflect recall pressure (unverified locally; a recall audit would test this).

    Cancer register and children's immunisation

    The cancer register records 1,716 patients (3.9% prevalence; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 24 months reaches 98.8% (England 92.2%). At age 5, MMR dose 1 reaches 94.9%, while MMR dose 2 is 86.3% (8.6 pp lower; 8.7 pp below the 95.0% target) and the 4-in-1 booster is 82.1% (12.9 pp below target).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months90.8%

    England 91.0%

    6-in-1 complete primary course at 24 months98.8%

    England 92.2%

    MMR dose 1 at 24 months97.7%

    England 88.3%

    MMR dose 2 at age 586.3%

    England 82.8%

    4-in-1 pre-school booster at age 582.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    Across NHS Greater Manchester ICB in 2022, 55.6% of staged cancers (6,491 of 11,679) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% of all 16,492 registered cancers. Closing this gap across the ICB would require an estimated 2,268.2 additional early-stage cases annually. While PCN cervical screening reaches 73.5% (England 66.8%), three-year change is -1.5% (England -1.0%) and coverage falls to 66.3% at King Street Medical Centre. Staging reflects wider system diagnostic pathways rather than PCN performance.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Tameside and Glossop Integrated Care NHS Foundation Trust, 62-day referral to treatment was 76.7676%, trailing the 85.0% standard by 8.2 pp (NHS Greater Manchester Integrated Care Board reached 75.7262%, 9.3 pp below standard). The trust met the 28-day faster diagnosis standard at 82.4757% (7.5 pp above the 75.0% standard; ICB 79.5261%) and the 31-day combined standard at 96.25% (0.2 pp above the 96.0% standard; ICB 96.4937%). While the PCN cancer register grew +15.2% over 2023 to 2025 (England +9.0%) to 1,716 patients, these waiting times describe trust and ICB performance rather than PCN delivery.

    Pathways within standard (%)Tameside and Glossop Integrated CareNorthern Care AllianceManchesterGreater Manchester ICBEngland
    28-day faster diagnosis (75%)82.4875.2080.0679.5379.32
    31-day treatment (96%)96.2594.5492.5496.4992.50
    62-day referral to treatment (85%)76.7778.6572.8575.7371.16
    Diagnostic waits over 6 weeks (%)Tameside and Glossop Integrated CareNorthern Care AllianceManchesterEngland
    MRI0.005.0911.6821.40
    CT0.184.1014.669.92
    Echocardiography0.0031.484.9128.48
    Colonoscopy1.5140.044.5130.83
    Gastroscopy5.4536.4829.3529.02
    All 15 DM01 tests0.8015.718.9823.14
    Community services activityTameside residentsGreater Manchester ICB
    Care contacts50,685573,310
    Referrals9,45094,470
    Patients with a contact15,790183,535

    Community services (residents of Tameside), Jun 2026 (provisional). In the Community Services Dataset (Jun 2026 (provisional)), 52.1% of community contacts for borough residents were with adults aged 65+ (26,410 of 50,685 contacts). Across the PCN, 18.0% of registered patients are aged 65+ (7,848 patients) and 1,716 are on the cancer register (3.9%), though community contacts were not captured at PCN level.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Vaccination achievement spans 74.8 pp and phone access spans 28.4 pp across practices

    In 2025/26, overall QOF achievement was 89.0% at Millbrook Medical Practice, while achievement at Staveleigh Medical Centre was 97.2%; England averaged 92.5%. Across England, vaccination and immunisation domain achievement was 55.2%. In that domain, achievement was 16.4% at Millbrook Medical Practice, while achievement was 91.2% at Mossley Medical Practice.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    St. Andrew's10644.291.6%73.3%93.8%
    King Street9760.582.8%72.7%89.8%
    Grosvenor11135.485.9%81.0%89.7%
    Lockside12726.985.3%73.0%89.3%
    Town Hall Surgery9646.774.6%68.4%87.0%
    Staveleigh10342.780.3%73.3%86.4%
    Millbrook Medical936.863.2%70.9%83.0%
    Mossley Medical9015.267.3%71.8%81.9%
    Pike Medical956.663.2%71.6%75.6%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNTameside (LAD)AssetPCNTameside (LAD)
    Care homes (catchment)13 (509 beds)n/aSchools (catchment)49n/a
    Children's centres516Places of worship31104
    Libraries27Homelessness support (VCS)n/a2
    Primary schools (LA maintained)922Primary academies846

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Standardised asthma review and inhaler recall

    Annual asthma reviews cover 64.5% of 3,260 registered patients (England 65.7%, ICB 66.2%), leaving an estimated 1,157 patients without a recorded review in 12 months. For discussion: the PCN could run a standardised recall search and offer after-school or school-holiday review slots alongside inhaler prescribing checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Cardiovascular and chronic disease recall audit

    Across 25 measures, 15 trail England's 2023 to 2025 change, led by heart failure reviews (-4.0% versus +8.7%), non-frail diabetes HbA1c <= 58 mmol/mol (-1.8% versus +4.4%), and hypertension control (-1.0% versus +3.6%). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school MMR2 and booster recall

    In Q1 2025/26 (cohort 117), age-5 MMR1 reaches 94.9%, but MMR2 is 86.3% (8.6 pp lower; 8.7 pp below the 95.0% standard) and the 4-in-1 booster is 82.1% (12.9 pp below standard). Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Care home MDT capacity review (p2)Count of care home beds in PCN catchmentFit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026PCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Smoking cessation offer audit (p4)Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension recall audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and access review (p9)GPPS good overall experience of the practice10YHP, hospital to communityPractice
    Option 1 · Standardised asthma review and inhaler recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · Cardiovascular and chronic disease recall audit (p12)Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapyCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school MMR2 and booster recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15